zurück zur Startseite
Zentrale Tel.: 06221-560
Translational Lung Research Center Heidelberg

CANCERALIA—Development of novel diagnostic and therapeutic approaches to improve patient outcome in lung and pancreatic tumours

Opens external link in new windowCANCERALIA is a project co-funded by the European Commission’s Seventh Framework Programme for Research and Technological Development (01/04/2011 - 30/09/2014). The main objective of this project is to study the role of the lipogenic (Kennedy) pathway and Rho GTPases in lung and pancreatic cancer. The ultimate goal is the improvement of patient survival by using a multidisciplinary approach, focused in these two pathways that are likely to be universally altered in cancer and that are mechanistically linked. Key to the success of the project is our understanding of a set of genes involved in phospholipid metabolism, including upstream regulators such as Rho GTPases and their effectors (defined as the “CANCERALIA” selected genes).
Further specific research objectives are the identification of novel therapeutic targets and markers of resistance to standard treatments; the development of effective combinatorial treatments and better assays for diagnosis and prognosis that will support the development of novel targeted and personalized therapies.
Prof. Dr. Francisco Real, CNIO, Madrid, Spain, is the coordinator of this project. The Thoraxklinik at Heidelberg University Hospital is partner in the lung cancer arm of the project. Opens internal link in current windowProf. Michael Thomas is the lead oncologist and advisor on the clinical aspects of the lung cancer arm. Opens internal link in current windowDr. Michael Meister heads the translational science unit, which provides lung tissue, DNA and RNA archived in the Opens internal link in current windowLung Biobank of the Thoraxklink.




Marien E, Meister M, Muley T, Gomez Del Pulgar T, Derua R, Spraggins JM, Vande Plas R, Vanderhoydonc F, Machiels J, Binda MM, Dehairs J, Willette Brown J, Hu Y, Dienemann H, Thomas M, Schnabel PA, Caprioli RM, Lacal JC, Waelkens E, Swinnen JV. (2016). Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma.
Oncotarget. 15:12582-12597.


Marien E, Meister M, Muley T, Fieuws S, Bordel S, Derua R, Spraggins J, Van de Plas R, Dehairs J, Wouters J, Bagadi M, Dienemann H, Thomas M, Schnabel PA, Caprioli RM, Waelkens E, Swinnen JV, (2015). Non-small cell lung cancer (NSCLC) is characterized by dramatic changes in phospholipid profiles. Int J Cancer, 137:1539-1548.



Select languageSelect language
Print Diese Seite per E-Mail weiterempfehlen